

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

Aeterna Zentaris Inc.  
Form 6-K  
October 29, 2004

FORM 6-K  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of October 2004

AETERNA ZENTARIS INC.

-----  
(Formerly named AETerna Laboratories Inc.)

1405, boul. du Parc-Technologique  
Quebec, Quebec  
Canada, G1P 4P5

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports  
under cover of Form 20-F or Form 40-F.

Form 20-F                      Form 40-F                      X  
-----    -----

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934

Yes                      No                      X  
-----    -----

If "Yes" is marked, indicate below the file number assigned to the registrant in  
connection with Rule 12g3-2(b): 82-  
-----

DOCUMENTS INDEX

DOCUMENTS	DESCRIPTION
-----	-----
1.	Press release dated October 28, 2004 - AETerna Zentaris Announces Third Quarter Financial Results Conference Call and Webcast

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

[AETERNA ZENTARIS LOGO]

AETERNA ZENTARIS INC. 1405 du Parc-Technologique Blvd.  
Quebec (Quebec) Canada G1P 4P5 T 418 652-8525 F 418 652-0881  
www.aeternazentaris.com

PRESS RELEASE  
For immediate release

AETERNA ZENTARIS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS  
CONFERENCE CALL AND WEBCAST

QUEBEC CITY, CANADA, OCTOBER 28, 2004 - AETerna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) announced that its quarterly conference call and webcast have been scheduled for Thursday, November 4, 2004 at 10:00 a.m. Eastern time. The call will follow the press release of AETerna Zentaris' third quarter 2004 financial results issued earlier on the same day. Participants may access the live webcast via the Company's website at [www.aeternazentaris.com](http://www.aeternazentaris.com) in the "investors" section, or by telephone using the following numbers: 416-640-4127, 514-807-8791 or 1-800-814-4941.

A replay of the webcast will also be available on the website for a period of 30 days.

AETerna Zentaris is a biopharmaceutical company with an extensive portfolio of marketed and development-stage products in oncology, endocrine therapy and infectious diseases.

-30-

CONTACTS:

MEDIA RELATIONS

Paul Burroughs  
(418) 652-8525 ext. 406  
[paul.burroughs@aeternazentaris.com](mailto:paul.burroughs@aeternazentaris.com)

INVESTOR RELATIONS

Jacques Raymond  
(418) 652-8525 ext. 360  
[jacques.raymond@aeternazentaris.com](mailto:jacques.raymond@aeternazentaris.com)

U.S. INVESTOR RELATIONS

Lippert/Heilshorn & Associates  
Kim Golodetz  
(212) 838-3777  
[kgolodetz@lhai.com](mailto:kgolodetz@lhai.com)

EUROPE

Matthias Seeber  
+49 69 42602 3425  
[matthias.seeber@zentaris.de](mailto:matthias.seeber@zentaris.de)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of

## Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AETERNA ZENTARIS INC.

Date: October 28, 2004  
-----

By: /s/ Mario Paradis  
-----

Mario Paradis  
Senior Finance Director and  
Corporate Secretary